|Bid||154.25 x 200|
|Ask||154.66 x 900|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||14.63|
|Dividend & Yield||4.60 (3.01%)|
|1y Target Est||N/A|
According to a March 2016 report by QuintilesIMSHealth, the biologics market is estimated to reach $390 billion by 2020.
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Amgen’s (AMGN) Xgeva was launched commercially in 2010 and is marketed primarily in the US and Europe. The drug crossed the $1 billion annual revenue mark in 2013.